US FDA inspection of Apitoria Pharma Unit-V ends with 3 observations

Business Updates View source PDF Explain this filing

AUROPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.0%Reaction day

₹1195.10

prior close

₹1200.00

announcement price

After-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)-0.1%-0.9% vs market

Pharmaceuticals peers, median of 155sector-0.1%-0.9% vs sector

On the reaction day the stock moved 0.9 pts less than Nifty Midcap 150 and 0.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.3

10m

-1.2

15m

-1.3

30m

-1.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.0-0.1-0.9-0.1-0.9

Next day

-1.7-0.8-0.8-0.6-1.1

-0.3-1.4+1.1-1.3+1.0

+1.3-1.2+2.5-1.4+2.7

+2.5-0.0+2.5-0.6+3.1

+2.4+0.8+1.6-0.0+2.5

+1.5+0.4+1.1-0.1+1.6

15d

+3.2+1.6+1.6+0.7+2.5

-2.4-0.8-1.6-2.8+0.4

-0.8-0.8+0.0-4.9+4.1

+6.4-9.0+15.4-10.9+17.3

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 155Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The US FDA inspected Unit-V, an API manufacturing facility of Apitoria Pharma Private Limited, a wholly owned subsidiary of Aurobindo Pharma, from December 1 to December 12, 2025, at Pashamylaram, Telangana. A Form 483 was issued with 3 procedural observations. The company will respond to the FDA within stipulated timelines. There is no impact on facility operations.

Likely market impact

Minor procedural observations with no operational impact; neutral to slightly negative for near-term stock sentiment.